Bernie Haffey Named Chief Commercial Officer at SightLife Surgical

May 12, 2017: By Joan McKenna

SightLifeSurgicalPaul Bernard “Bernie” Haffey has joined SightLife Surgical as its first chief commercial officer.

SightLife Surgical, founded in 2016, is a Seattle-based for-profit subsidiary of SightLife that provides comprehensive services to support ophthalmic surgeons, from corneal tissue and devices to reimbursement consulting and political advocacy.

“Given our ambitions to accelerate discoveries that will benefit the cornea world, from surgeons to patients, Bernie’s background launching emerging medical technology companies, as well as his proven history of creating shareholder value, will help us reach our goal to eliminate corneal blindness by 2040,” said Monty Montoya, SightLife Surgical president and CEO.

Most recently, Haffey served as president and CEO of Nexis Vision, Inc., and president and CEO of NDO Surgical, Inc. He also served as executive vice president and chief commercial officer at Summit Technology, Inc., and as executive vice president and chief commercial officer at IntraLase Corp. In addition to his role at SightLife, Bernie serves as president of 2020 Management Consulting, Inc.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Refocus Completes PMA Application for VisAbility as Treatment for Presbyopia

Novaliq’s NovaTears+Omega-3 Approved in Europe for Dry Eye

CooperVision Acquires Paragon Vision Sciences for $80 Million

AYOXXA Biosystems Launches Test for Biomarkers in Retinal Disease

Glaukos Announces New Patent for Glaucoma Stent Implanted in Schlemm’s Canal

Fortress Biotech Forms Tamid Bio Subsidiary; Lead Candidate is Ophthalmic Gene Therapy for MPS I

Samsung Launches App that Adjusts QLED TV Settings for Color-blind Viewers

Solar Eclipse Burns Crescent Wound in Woman’s Unprotected Retina

US Judge Refuses to Dismiss Allergan Suit against Imprimis

BioLight Sells IOPtima to Chengdu Kanghong Pharmaceutical Group for $56 Million

Regeneron Ending Eylea, Nesvacumab Combo Program

UK Retinal Drugmaker Exonate Forms Clinical Advisory Board

US FDA Approves RxSight’s Light Adjustable Lens and Light Delivery Device

EMA to Move to Amsterdam due to Brexit

First Subject Dosed in Nevakar’s Phase III Trial of NVK-002 for Myopia in Children

ProQR Doses First Patient in Phase I/II Trial for Leber’s Congenital Amaurosis 10

Aston EyeTech Raises $6.6 Million in Series A Equity Round

Ellex Raises $17.7 Million in Private Placement

Genentech’s Lampalizumab Fails Second Phase III Study in Geographic Atrophy

Judge Declares Mistrial in Corruption Trial of Melgen, Menendez

Coming soon

2017 Dry Eye Products Report: A Global Market Analysis for 2016 to 2022